BANK VONTOBEL/CALL/BIOGEN IDEC/330/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 02:02:11 2024-06-13 pm EDT | ||
| 0.028 EUR | +21.74% |
|
| Current month | -61.11% | ||
| 1 month | -73.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 0.028 | +21.74% |
| 24-06-12 | 0.023 | -54.90% |
| 24-06-11 | 0.051 | -33.77% |
| 24-06-10 | 0.077 | 0.00% |
| 24-06-07 | 0.077 | -13.48% |
Delayed Quote Deutsche Boerse AG
Last update June 13, 2024 at 02:02 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM36AW |
| ISIN | DE000VM36AW4 |
| Date issued | 2023-10-18 |
| Strike | 330 $ |
| Maturity | 2024-09-20 (99 Days) |
| Parity | 10 : 1 |
| Emission price | 1.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.99 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.022 € |
| Spread % | 36.67% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
233.8
USD
Average target price
284.6
USD
Spread / Average Target
+21.73%
- Stock Market
- Warrants
- Warrant
